Receiving lymphodepleting chemotherapy prior to commercial CAR-T administration for multiple myeloma, leukemia, or lymphoma
Adequate bone marrow function to receive lymphodepleting chemotherapy
Renal function \</= 60mL/min/1.73m2
ECOG 0-2
You may not be if
Relative CNS disorders
Active uncontrolled infection or any other concurrent disease or medical condition that was deemed to interfere with the conduct of the study as judged by the investigator
Use of therapeutic dose systemic corticosteroids (defined as \>20mg/day prednisone or equivalent) within 72 hours of CAR-T administration
Clareo Health | CAR T-cell Therapy in Patients With Renal Dysfunction
